AR128985A1 - Forma cristalina de lanifibranor - Google Patents
Forma cristalina de lanifibranorInfo
- Publication number
- AR128985A1 AR128985A1 ARP230100832A ARP230100832A AR128985A1 AR 128985 A1 AR128985 A1 AR 128985A1 AR P230100832 A ARP230100832 A AR P230100832A AR P230100832 A ARP230100832 A AR P230100832A AR 128985 A1 AR128985 A1 AR 128985A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline form
- lanifibranor
- diffraction pattern
- ray
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305456 | 2022-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128985A1 true AR128985A1 (es) | 2024-07-03 |
Family
ID=81326293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100832A AR128985A1 (es) | 2022-04-05 | 2023-04-04 | Forma cristalina de lanifibranor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250243192A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4504725A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025511847A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250002337A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119301120A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128985A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023250118A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3247273A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316075A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024012348A (cg-RX-API-DMAC7.html) |
| PY (1) | PY2324870A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202404966A (cg-RX-API-DMAC7.html) |
| UY (1) | UY40216A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023194339A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022325334A1 (en) * | 2021-08-12 | 2024-02-22 | Inventiva | Crystal form of lanifibranor, preparation method therefor, and use thereof |
| JP2026501899A (ja) | 2023-01-19 | 2026-01-16 | インベンティバ | ラニフィブラノール製剤 |
| WO2024251730A1 (en) | 2023-06-05 | 2024-12-12 | Inventiva | Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition |
| AR133887A1 (es) * | 2023-09-22 | 2025-11-12 | Inventiva | Método de fabricación de lanifibranor |
| IL330214A (en) | 2023-12-21 | 2026-08-01 | Inventiva | Combination therapy for the prevention and/or treatment of liver disease |
| AU2024409290A1 (en) | 2023-12-21 | 2026-08-06 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| WO2025191292A1 (en) | 2024-03-15 | 2025-09-18 | Inventiva | Methods and monitoring of treatment with lanifibranor |
| WO2025191117A1 (en) | 2024-03-15 | 2025-09-18 | Inventiva | Prevention of blood disorders in patient treated with a ppar agonist |
| TW202604485A (zh) | 2024-05-17 | 2026-02-01 | 法商因文帝華公司 | 患有肝損傷患者肝疾病之治療 |
| WO2026115290A1 (en) | 2024-11-28 | 2026-06-04 | Inventiva | Non-invasive monitoring of nash treatment with lanifibranor |
| WO2026125286A1 (en) | 2024-12-09 | 2026-06-18 | Inventiva | Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| WO2022122014A1 (zh) | 2020-12-11 | 2022-06-16 | 苏州科睿思制药有限公司 | Lanifibranor的晶型及其制备方法和用途 |
| WO2022143479A1 (zh) | 2020-12-29 | 2022-07-07 | 广东东阳光药业有限公司 | 一种化合物的固体形式及其制备方法和用途 |
| US20240246949A1 (en) | 2021-06-10 | 2024-07-25 | Teva Pharmaceuticals International Gmbh | Solid state forms of lanifibranor and process for preparation thereof |
| CN115466252A (zh) | 2021-06-11 | 2022-12-13 | 上海希迈医药科技有限公司 | 一种Lanifibranor的晶型及其制备方法 |
| AU2022325334A1 (en) | 2021-08-12 | 2024-02-22 | Inventiva | Crystal form of lanifibranor, preparation method therefor, and use thereof |
-
2023
- 2023-03-31 TW TW112112450A patent/TW202404966A/zh unknown
- 2023-04-04 US US18/854,287 patent/US20250243192A1/en active Pending
- 2023-04-04 JP JP2024559386A patent/JP2025511847A/ja active Pending
- 2023-04-04 AR ARP230100832A patent/AR128985A1/es unknown
- 2023-04-04 KR KR1020247036771A patent/KR20250002337A/ko active Pending
- 2023-04-04 AU AU2023250118A patent/AU2023250118A1/en active Pending
- 2023-04-04 CN CN202380042246.2A patent/CN119301120A/zh active Pending
- 2023-04-04 IL IL316075A patent/IL316075A/en unknown
- 2023-04-04 EP EP23717474.3A patent/EP4504725A1/en active Pending
- 2023-04-04 WO PCT/EP2023/058743 patent/WO2023194339A1/en not_active Ceased
- 2023-04-04 CA CA3247273A patent/CA3247273A1/en active Pending
- 2023-04-04 PY PY202302324870A patent/PY2324870A/es unknown
- 2023-04-10 UY UY0001040216A patent/UY40216A/es unknown
-
2024
- 2024-10-04 MX MX2024012348A patent/MX2024012348A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012348A (es) | 2024-11-08 |
| JP2025511847A (ja) | 2025-04-16 |
| EP4504725A1 (en) | 2025-02-12 |
| WO2023194339A1 (en) | 2023-10-12 |
| TW202404966A (zh) | 2024-02-01 |
| UY40216A (es) | 2023-10-31 |
| CA3247273A1 (en) | 2023-10-12 |
| IL316075A (en) | 2024-12-01 |
| PY2324870A (es) | 2023-10-27 |
| CN119301120A (zh) | 2025-01-10 |
| US20250243192A1 (en) | 2025-07-31 |
| KR20250002337A (ko) | 2025-01-07 |
| AU2023250118A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124911A1 (es) | Sólidos cristalinos del inhibidor mek n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y usos de los mismos | |
| CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| UY29277A1 (es) | Derivados de benzamidas (4(4-(1-isopropil-2-metil-1h-imidazol-5-il)-pirimidin-2-il)amino)sustitudas, composiciones que los contienen, procedimiento de preparación y aplicaciones | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| AR052948A1 (es) | DERIVADOS DE ACETILENIL-PIRAZOLO-PIRIMIDINA COMO ANTAGONISTAS DE MGLUR2, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL SNC | |
| PE20240114A1 (es) | Inhibidor de integrina y usos de este | |
| Rojo et al. | The synthesis and characterisation of strontium and calcium folates with potential osteogenic activity | |
| PE20252755A1 (es) | Formas cristalinas de un inhibidor de ras | |
| HN2001000110A (es) | 5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis | |
| JPH02503318A (ja) | 化合物 | |
| KR20200103031A (ko) | 신규한 mtor 저해제 화합물 | |
| AU2013301156A1 (en) | Process for the preparation of pemetrexed and lysin salt thereof | |
| PE20251400A1 (es) | Derivados de co-cristales de 4-[4-[3-cloro-4-[1- (2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con acido galico y amida nicotinica | |
| Srivastava et al. | 4-(Ethoxycarbonyl) phenyl-1-amino-oxobutanoic acid–chitosan complex as a new matrix for silver nanocomposite film: Preparation, characterization and antibacterial activity | |
| CO6270318A2 (es) | Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465 | |
| Xie et al. | Anti-AIDS (acquired immune deficiency syndrome) agents. 17. New brominated hexahydroxybiphenyl derivatives as potent anti-HIV agents | |
| PE20231071A1 (es) | Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1- il)fenil]-6-oxo-1,6-dihidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15- tetraazatriciclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona | |
| Ouédraogo et al. | 2-Oxo-2H-chromen-7-yl 4-tert-butylbenzoate | |
| Adamovich et al. | Biologically active protic (2-hydroxyethyl) ammonium ionic liquids. Liquid aspirin | |
| ES2527354T3 (es) | Anhidrato de 8-cloro-3-pentil-3,7-dihidro-1H-purina-2,6-diona 2-amino-2-(hidroximetil)-1,3-propanodiol para el tratamiento de enfermedades | |
| AR064107A1 (es) | Polimorfos de motilida, un procedimiento para su preparacion y una formulacion farmaceutica | |
| PE20241624A1 (es) | Sal derivada de triazolona como inhibidor de elastasa de neutrofilos | |
| AR083256A1 (es) | Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico | |
| AR131692A1 (es) | Formas cristalinas o sales de un compuesto deuterado |